Voor degenen die geen Engelse vertaler hebben:
MolMed, the biotechnology company, sells 2% to 0.5220 euro when there are approximately two hours after the session.
What today might be the third downward below after nearly doubling the quote in less than two months.
Earlier this week the title marked the peak of the last two years to 0.6370 euro.
Volumes are down compared to the record yesterday of 34 million shares traded, the highest daily amount for 5 years. So far they have transited 9 million shares.
With 225 million shares traded, September is a month from the historical record. In August they had passed 59 million shares, 12 million in July.
Despite the descent, from the beginning of 2016, the performance amounted to + 45%, one of the best Business Square.
Graphically, the movement of the last three sessions (with the simultaneous contraction in volumes) could signal the start of a physiological phase of consolidation in a range that sees extremes provisionally placed at 0.48 / 0.50 and 0.60 / 0 , 63 euro.
Operations. The recent break of EUR 0.56 area has pushed prices close to the target set in the range 0.68 / 0.70 euro triggering profit-taking.
As suggested in previous comments, the decline towards 0.48 / 0.50 euro is to be exploited to buy on weakness. Target always positioned in the upper part of the indicated range.
Place a stop loss prudent to first close below 0.45 euro.